Skip to main content
. 2020 Dec 11;10(2):718–727. doi: 10.1002/cam4.3639

FIGURE 2.

FIGURE 2

MiR‐1 reduced the effects of EGFR‐TKIs. Results of cell viability assay (n = 6). In PC9, significant cell proliferation was observed in the miR‐1 transfection group at 48 and 72 h after treatment with gefitinib or erlotinib (gefitinib/erlotinib: after 48 h; p = 0.0002/p = 0.0001, after 72 h; p = 0.0002/p = 0.0291)